Template:Reteplase: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 17: | Line 17: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Reteplase use in specific populations|Use in Specific Populations]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Reteplase use in specific populations|Use in Specific Populations]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Reteplase description|Description]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Reteplase description|Description]] | ||
Latest revision as of 19:35, 6 February 2014
| Reteplase |
|---|
| Retavase® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Reteplase |
| ClinicalTrials.gov |